Fetal Hypoxia and Its Monitoring in Pregestational Diabetic Pregnancies

2005 ◽  
pp. 222-229
Author(s):  
Kari A. Teramo ◽  
Vilho K. Hiilesmaa
Keyword(s):  
Fetal Hypoxia

Diagnostics of the chronic fetal hypoxia during pregnancy

1980 ◽  
Vol 61 (4) ◽  
pp. 58-59
Author(s):  
S. Ya. Malinovskaya ◽  
I. P. Laricheva ◽  
P. A. Klimenko ◽  
Z. H. Baideva
Keyword(s):  
Amniotic Fluid ◽  
Pregnant Women ◽  
Cardiac Activity ◽  
The State ◽  
Placental Lactogen ◽  
Fetal Hypoxia

In order to clarify the significance of various methods for determining the state of the fetus during its hypoxia, we studied the content of placental lactogen (PLH) in the blood and amniotic fluid, the activity of histidase and urocaninase in them, and also studied the cardiac activity of the fetus using the oxytocin test in 109 pregnant women.

Effect of fetal hypoxia on seizure susceptibility in rats

1995 ◽  
Vol 57 (2) ◽  
pp. 315-318 ◽  
Author(s):  
Pier Luigi De Riu ◽  
Piero Mameli ◽  
Antonella Becciu ◽  
Maria Elena Simula ◽  
Ombretta Mameli
Keyword(s):  
Seizure Susceptibility ◽  
Fetal Hypoxia

Fetal erythropoietin levels in pregnancies complicated by meconium passage: Does meconium suggest fetal hypoxia?

2000 ◽  
Vol 183 (1) ◽  
pp. 188-190 ◽  
Author(s):  
A JAZAYERI ◽  
L POLITZ ◽  
J TSIBRIS ◽  
T QUEEN ◽  
W SPELLACY
Keyword(s):  
Fetal Hypoxia

In Vivo Neurochemical Characterization of Developing Guinea Pigs and the Effect of Chronic Fetal Hypoxia

2016 ◽  
Vol 41 (7) ◽  
pp. 1831-1843 ◽  
Author(s):  
Wen-Tung Wang ◽  
Phil Lee ◽  
Yafeng Dong ◽  
Hung-Wen Yeh ◽  
Jieun Kim ◽  
...  
Keyword(s):  
Guinea Pigs ◽  
Fetal Hypoxia

scholarly journals False Positive Values of Biomarkers of Prenatal Screening on Chromosomopathy as Indicators of a Risky Pregnancy

2011 ◽  
Vol 30 (2) ◽  
pp. 126-130 ◽  
Author(s):  
Jasmina Durković ◽  
Luka Anđelić ◽  
Bojana Mandić ◽  
Denis Lazar
Keyword(s):  
Genetic Screening ◽  
False Positive ◽  
Prenatal Screening ◽  
Protein A ◽  
First Trimester ◽  
Maternal Serum ◽  
Fetal Hypoxia ◽  
Beta Hcg ◽  
First Trimester Of Pregnancy ◽  
Fetal Karyotype

False Positive Values of Biomarkers of Prenatal Screening on Chromosomopathy as Indicators of a Risky PregnancyGenetic screening on chromosomopathy has been performed on 2000 pregnant women in their first trimester of pregnancy by determining Pregnancy associated plasma protein-A and free-beta HCG biomarkers in maternal serum. After obtaining a normal fetal karyotype, the pathological values of the biomarkers have been correlated with other pregnancy disorders, and the possible causes of the positive genetic screening have been tested. 340 false positive biomarkers (17%) have been detected. The increased free-beta HCG (48.24%) had a significant influence. A significant correlation (p > 0.01) between the increased free-beta HCG and bleeding during pregnancy has been established. Complications occurred in 78.52% pregnancies with pathological biomarkers, MISSed in 13.82%, miscarriages in 10.88%, induced pregnancy terminations caused by fetal anomalies in 8.82% and births with disturbed fetal vitality in 45%. The research results have shown a significant correlation (p > 0.01) between the increased value of the free-beta HCG biomarkers and fetal hypoxia. The false positive genetic screening, caused by the increased free-beta HCG, can indicate placental dysfunction and fetal vitality disruption.

scholarly journals miR-16-5p, miR-103-3p, and miR-27b-3p as Early Peripheral Biomarkers of Fetal Growth Restriction

2021 ◽  
Vol 9 ◽  
Author(s):  
Salvatore Tagliaferri ◽  
Pasquale Cepparulo ◽  
Antonio Vinciguerra ◽  
Marta Campanile ◽  
Giuseppina Esposito ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Gestational Age ◽  
Fetal Growth Restriction ◽  
Late Onset ◽  
Maternal Blood ◽  
Growth Restriction ◽  
Therapeutic Interventions ◽  
Control Group ◽  
Fetal Hypoxia ◽  
Blood Samples

Current tests available to diagnose fetal hypoxia in-utero lack sensitivity thus failing to identify many fetuses at risk. Emerging evidence suggests that microRNAs derived from the placenta circulate in the maternal blood during pregnancy and may be used as non-invasive biomarkers for pregnancy complications. With the intent to identify putative markers of fetal growth restriction (FGR) and new therapeutic druggable targets, we examined, in maternal blood samples, the expression of a group of microRNAs, known to be regulated by hypoxia. The expression of microRNAs was evaluated in maternal plasma samples collected from (1) women carrying a preterm FGR fetus (FGR group) or (2) women with an appropriately grown fetus matched at the same gestational age (Control group). To discriminate between early- and late-onset FGR, the study population was divided into two subgroups according to the gestational age at delivery. Four microRNAs were identified as possible candidates for the diagnosis of FGR: miR-16-5p, miR-103-3p, miR-107-3p, and miR-27b-3p. All four selected miRNAs, measured by RT-PCR, resulted upregulated in FGR blood samples before the 32nd week of gestation. By contrast, miRNA103-3p and miRNA107-3p, analyzed between the 32nd and 37th week of gestation, showed lower expression in the FGR group compared to aged matched controls. Our results showed that measurement of miRNAs in maternal blood may form the basis for a future diagnostic test to determine the degree of fetal hypoxia in FGR, thus allowing the start of appropriate therapeutic interventions to alleviate the burden of this disease.

Sign in / Sign up

Export Citation Format

Share Document